868 abstracts found.



Results filter

T cell receptor gene transfer to target the Epstein-Barr virus-associated malignancy nasopharyngeal carcinoma

Year:

Session type:

Yong Zheng, Lee Machado, Beatrice Johnson, Christine James, Gregory Parsonage, Steven P. Lee

Institute of Cancer Study, Medical School, University of Birmingham, UK


Should all patients receiving capecitabine be screened for hypertrigylceridaemia? A prospective audit of incidence and severity

Year:

Session type:

Caroline Michie1, Maria Sakala1, Iain Rivans1, Mark Strachan2, Sally Clive1

1Edinburgh Cancer Centre, Western General Hospital, UK, 2Western General Hospital, Edinburgh, UK


A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer

Year:

Session type:

Ami Sabharwal1, Pippa Corrie2, Rachel Midgley1, Cheryl Palmer2, Joanne Brady1, Peter Mortimer3, Amanda Watson4, Geoff Margison4, Mark Middleton1

1University of Oxford, Churchill Hospital, Oxford, UK, 2Addenbrookes Hospital, Cambridge, UK, 3Kudos Pharmaceuticals, Cambridge, UK, 4Paterson Institute for Cancer Research, Manchester, UK


A trial of continuous low dose chemotherapy combined with celecoxib for patients with advanced cancer

Year:

Session type:

Omar Khan1, Andrew Blann2, Miranda Payne1, Mark Middleton1, Andrew Protheroe1, Denis Talbot1, Oksana Kirichek1, Marian Taylor1, Cheng Han1, Adrian Harris1

1University of Oxford, UK, 2University of Birmingham, UK


Evidence that hexa histidine tags on therapeutic proteins are not immunogenic in patients

Year:

Session type:

Surinder Sharma1, Natalie Griffin1, Steve Cleverley2, Hassan Shahbakhti1, Heide Kogelberg1, Berend Tolner1, Richard Begent1, Kerry Chester1

1University College London Cancer Institute, London, UK, 2TouchDown Bioinnovation, Bemmel, Netherlands


Role of intensity modulated radiotherapy in the treatment of soft tissue sarcoma arising close to dose limiting normal structures

Year:

Session type:

Ananya Choudhury, Win Soe, Philip Whitehurst, James Wylie

Christie Hospital, Manchester, UK


IMPORT LOW re-visited: how strategic trial management has increased average monthly accrual (CRUK06/003)

Year:

Session type:

Charlotte Coles1, Jenny Titley2, Judith Bliss2, Charlie Chan3, Laura Ciurlionis4, Jo Haviland2, Mark Sydenham2, Yat Tsang4, Gordon Wishart1, John Yarnold4, IMPORT TMG5

1Addenbrooke's Hospital, Cambridge, UK, 2The Institute of Cancer Research, Sutton, UK, 3Cheltenham General Hospital, Cheltenham, UK, 4Mount Vernon Hospital, Northwood, UK, 5National Health Service, Nationwide, UK


IMPORT HIGH development of comprehensive and practical radiotherapy planning solutions may facilitate trial recruitment (CRUK06/003)

Year:

Session type:

Yat Tsang1, Charlotte Coles2, Ellen Donovan3, Judith Bliss4, Laura Ciurlionis1, Jo Haviland4, Jenny Titley4, John Yarnold4, IMPORT TMG5

1Mount Vernon Hospital, Northwood, UK, 2Addenbrooke's Hospital, Cambridge, UK, 3The Royal Marsden Hospital, Sutton, UK, 4The Institute of Cancer Research, Sutton, UK, 5The National Health Service, Nationwide, UK


γH2AX: a target for imaging and systemic radiation therapy

Year:

Session type:

Bart Cornelissen, Kate Sleeth, Jody Mitchell, Sonali Darbar, Veerle Kersemans, Sean Smart, Katherine Vallis

Gray Institute for Radiation Oncology and Biology, University of Oxford, UK


Gold nanoparticles sensitise plasmid DNA and cancer cell lines to broad-spectrum and monochromatic kilo-voltage radiation

Year:

Session type:

Suneil Jain, Jonathan Coulter, Karl Butterworth, Wendy Hyland, Stephen McMahon, Mark Muir, Fred Currell, Kevin Prise, Joe O'Sullivan, David Hirst

Queens University Belfast, UK


Radiotherapy fraction size sensitivity modulated by DNA repair systems

Year:

Session type:

Navita Somaiah1, John Yarnold2, Kai Rothkamm3, Frances Daley1, Ann Pearson2, Thomas Helleday1

1Gray Institute for Radiation Oncology & Biology, Oxford, UK, 2Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK, 3Health Protection Agency, Centre for Radiation, Chemical & Environmental Hazards, Chilton, UK


Automated patient model construction and alignment to stereo video reconstructions for augmented reality guidance of robotic prostatectomy

Year:

Session type:

Dongbin Chen, Dan Stoyanov, Erik Mayer, Justin Vale, Anne Anstee, Ara Darzi, Guang-Zhong Yang, Philip Eddie Edwards

Imperial College London, UK


Radiolytic markers as biomarkers for breast cancer radiotherapy

Year:

Session type:

Miriam Dwek, Michael Douek

1University of Westminster, London, UK, 2Guy's & St. Thomas NHS Trust / Kings College, London, UK


A retrospective service evaluation of radiotherapy fractionation schedules in cerebral metastases at New Cross Hospital, Wolverhampton

Year:

Session type:

Ross Oliver Charles Elledge1, Roxy Khazaee-Farid1, Prakash Ramachandra2

1University of Birmingham, UK, 2New Cross Hospital, Wolverhampton, UK


Case Report: treatment of insulinoma related hypoglycaemia with Everolimus (RAD001) therapy

Year:

Session type:

Jonathan Chambers, William Berg

1Novartis, Oncology, Frimley, UK, 2Novartis, Global Medical Affairs, New Jersey, USA


Mesenchymal stem cells transformed by sequential retroviral transfection do not display radioresistance or upregulated DNA damage responses

Year:

Session type:

Susan Short, Christine Martindale, Mulugeta Worku, Juan Manuel Funes, Sonia Shah

University College London, UK


Efficient trial design for new cancer therapies

Year:

Session type:

Peter Hall1, Julia Brown1, David Cameron2, Christopher McCabe1

1University of Leeds, UK, 2National Cancer Research Network, Leeds, UK


Genetic pathways for the prediction of the effects of ionising radiation: low dose radiosensitivity and risk to normal tissue after radiotherapy

Year:

Session type:

Michelle McRobbie1, Michael Walter2, John Yarnold3, Peter O'Neill1

1University of Oxford, UK, 2University of Tuebingen, Germany, 3The Institute of Cancer Research, Sutton, UK


Breathlessness training in patients with intrathoracic malignancy: a comparison of low and high intensity programmes

Year:

Session type:

Miriam Johnson, Anne English, Sam Nabb, Alan Rigby, Rachael Barton

1Hull York Medical School, Hull, UK, 2Dove House Hospice, Hull, UK, 3University of Hull, UK, 4Hull and East Yorkshire Hospitals NHS Trust, Hull, UK


Over-expression of the base excision repair protein, DNA polymerase beta, is associated with resistance to oxaliplatin chemotherapy and sensitivity to radiotherapy

Year:

Session type:

Nils H. Nicolay1, Laura Sweet1, Jason Parsons1, Jian Yang1, Chris Harrington2, Raj Singh3, Patrick J. Johnston4, Thomas Helleday1, Grigory Dianov1, W. Gillies McKenna1, Ricky A. Sharma1

1Gray Institute for Radiation Oncology and Biology, University of Oxford, UK, 2Nottingham School of Science and Technology, Nottingham Trent University, UK, 3University of Leicester, UK, 4Queens University, Belfast, UK


The role of radiotherapy for aggressive fibromatosis

Year:

Session type:

Nooreen Alam1, Shaun Tolan1, Paula Mandall1, Lester Barr2, James Wylie1, Ananya Choudhury1

1Christie Hospital, Manchester, UK, 2University Hospital of South Manchester, UK


The use of hormone replacement therapy (HRT) for radiation induced premature menopause

Year:

Session type:

Jahangeer Malik, Alison Stillie, Mark Zahra

Edinburgh Cancer Centre, UK


Role of LATS1 in DNA damage signalling

Year:

Session type:

Robert Latusek, Cecilia Lundin, Thomas Helleday, Eric O'Neill

University of Oxford, UK


Micro-CT imaging for anatomical referencing in PET and SPECT: radiation dose, biological damage and image quality

Year:

Session type:

Veerle Kersemans, Philip Allen, Mick Woodcock, Mark Hill, Sean Smart

Gray Institute for radiation Oncology and Biology, Oxford, UK


A mechanistic study of the damage responses evoked by gold nanoparticles, both in the absence and presence of ionising radiation

Year:

Session type:

Jonathan Coulter, Suneil Jain, Karl Butterworth, Wendy Hyland, Mark Muir, Stephen McMahon, Fred Curell, Kevin Prise, David Hirst

Queens University Belfast, UK


Epigenetic regulation of the stem cell marker CD133 in prostate cancer

Year:

Session type:

Davide Pellacani, Anne T. Collins, Norman J. Maitland

University of York, UK


A double-blind, randomised, dose finding, phase II, multicentre study of Alpharadin (radium-223) for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC) EudraCT number: 2005-003680-22

Year:

Session type:

Christopher Parker1, Peter Hoskin2, Sarah Pascoe3, Ales Chodacki4, Charles Gillies O'Bryan-Tear5, Anita Lokna5

1Royal Marsden Hospital, Sutton, UK, 2Mount Vernon Hospital, Middlesex, UK, 3Derriford Hospital, Plymouth, UK, 4Hospital Chomutov, Chomutov, Czech Republic, 5Algeta ASA, Oslo, Norway


UK Urologists assessment and management of fracture risk in patients treated for prostate cancer

Year:

Session type:

Mohammad Azam Shaikh, Bhaskar Somani, Derek Byrne

Ninewells Hospital, Dundee, UK


CAP (comparison arm for ProtecT) trial: the design of a randomised controlled trial investigating the impact of population based prostate specific antigen (PSA) testing for prostate cancer

Year:

Session type:

Emma Turner1, Jenny Donovan1, Chris Metcalfe1, Freddie Hamdy2, David Neal3, Sian Noble1, Athene Lane1, Richard Martin1

1University of Bristol, UK, 2University of Oxford, UK, 3University of Cambridge, UK


FGFR3 mutation is not the initiating mutation in urothelial cell cancer

Year:

Session type:

Imran Ahmad1, Xue-Ru Wu2, Hing Y Leung1, Tomoko Iwata1, Owen J Sansom1

1Beatson Institute for Cancer Research, Glasgow, UK, 2New York University School of Medicine, New York, USA


Identification of Androgen receptor gene expression signatures in prostate cancer with high through-put validation

Year:

Session type:

Charlie Massie1, Ladan Fazli2, Andy Lynch1, Rory Stark1, Elena Grigorenko3, Naomi Sharma1, Helen Scott1, David Neal1, Ian Mills1

1CRUK Cambridge Research Institute, Cambridge, UK, 2The Prostate Centre at Vancouver General Hospital, Vancouver, Canada, 3BioTrove, Woburn, USA


β-Catenin induced senescence progresses to urothelial cell carcinoma

Year:

Session type:

Imran Ahmad1, Xue-Ru Wu2, Hing Y Leung1, Owen J Sansom1

1Beatson Institute for Cancer Research, Glasgow, UK, 2New York University School of Medicine, USA


Genetic profiling of prostate epithelial SP sub-populations

Year:

Session type:

Michael Brown1, Ben Grey1, Noel Clarke2

1University of Manchester, UK,2The Christie NHS Foundation Trust, Manchester, UK, 3Salford Royal Hope NHS Foundation Trust, Salford, UK


Developing dietary interventions for prostate cancer: systematic reviews and investigations of dietary change

Year:

Session type:

Kerry N L Avery1, J Athene Lane1, Steven Oliver2, David E Neal3, Freddie C Hamdy4, Jenny L Donovan1

1University of Bristol, UK, 2University of York, UK, 3Addenbrooke's Hospital, Cambridge, UK, 4John Radcliffe Hospital, Oxford, UK


Arachidonic acid primes human bone marrow stroma for prostate cancer metastasis

Year:

Session type:

Noel Clarke1, Claire Hart1, Ehsan Gazi1, Peter Gardner2, Michael Brown1

1The Christie NHS Foundation Trust, Manchester, UK, 2University of Manchester, UK


Growth of a subset of human prostate epithelial cells can be inhibited by gonadotropin releasing hormone receptor activation

Year:

Session type:

Kevin Morgan, Nicola Miller, Robert Millar

MRC Human Reproductive Sciences Unit, Edinburgh, UK


The ProtecT trial: evaluating the effectiveness of treatments for clinically localised prostate cancer

Year:

Session type:

J Athene Lane1, Jenny Donovan1, David Neal2, Michael Davis1, Liz Down1, Freddie Hamdy1

1University of Bristol, UK, 2Addenbrokes' Hospital, Cambridge, UK, 3University of Oxford, UK


Expression of the endogenous signaling regulator Sef predicts prostate cancer behaviour and alters the cell response to targeted inhibition of FGF receptors

Year:

Session type:

Tania Murphy, Steven Darvy, Satoshi Hori, M Mathers, C Robson, Vincent Gnanapragasam

University of Cambridge, UK


Mutation analysis of the MSMB gene and its upstream region in familial prostate cancer

Year:

Session type:

Zsofia Kote-Jarai1, Daniel Leongamornlert1, Malgorzata Tymrakiewicz1, Helen Field2, Michelle Guy1, Lynne O'Brien1, Rosemary Wilkinson1, Amanda Hall1, Kenneth Muir3, Aritaya Lophatananon3, Freddy Hamdy4, Jenny Donovan5, David Neal2, Douglas Easton2, Rosalind Eeles1

1The Institute of Cancer Research, Sutton, UK, 2University of Cambridge, UK, 3University of Nottingham, UK, 4University of Oxford, UK, 5University of Bristol, UK


Protease nexin 1 and metal metalloproteinase 9 levels affect expression of hedgehog proteins in a prostate model of cancer

Year:

Session type:

Chad McKee, Danmei Xu, Sheheryar Kabraji, Benedikt Kessler, Ruth Muschel

University of Oxford, UK


Effect of sulforaphane on global gene expression in a prostate-specific PTEN knockout mouse model

Year:

Session type:

Maria Traka1, Caroline Spinks1, Richard Ball2, Richard Mithen1

1Institute of Food Research, Norwich, UK, 2Norfolk and Norwich University Hospital, UK


Manipulating androgen receptor cofactors as a therapeutic strategy for prostate cancer

Year:

Session type:

Alwyn Dart, Bradley Spencer-Dene, Deepa Chotai, Jonathan Waxman, Charlotte Bevan

Imperial College London, UK


Abstract withdrawn

Year:

Session type:


Identification of multiple genetic variants which predispose to prostate cancer by genome-wide association in the PRACTICAL international consortium

Year:

Session type:

Ros Eeles1, Zsofia Kote-Jarai1, Michelle Guy1, David Neal2, Freddie Hamdy3, Jenny Donovan4, Ali Amin Al Olama2, Doug Easton2, PRACTICAL Consortium1

1The Institute of Cancer Research, Sutton, UK, 2University of Cambridge, UK, 3University of Oxford, UK, 4Bristol University, UK


Brca2 and Trp53 co-operate in the progression of mouse prostate neoplasia

Year:

Session type:

Jeff Francis, Afshan McCarthy, Alan Ashworth, Amanda Swain

Institute of Cancer Research, London, UK


Anemia does not affect the plasma clearance of chemotherapeutic drugs in cancer patients

Year:

Session type:

Vikram Gota1, Pankaj Patial1, Mohandas Mallath2

1ACTREC, Tata Memorial Centre, Navi Mumbai, India, 2Tata Memorial Hospital, Mumbai, India


Radiation therapy with Type II Anti-CD20 monoclonal antibody initiates extracellular signal-regulated Kinase/Mitogen-Activated protein kinasedependent cell death that overcomes resistance to apoptosis

Year:

Session type:

Waleed Alduaij, Andrey Ivanov, Sergei Krysov, Mark Cragg, Tim Illidge

1Paterson Institute for Cancer Research, University of Manchester, UK, 2University of Southampton, UK


Investigation of FLCN mutations in renal and colorectal cancers

Year:

Session type:

Michael Nahorski1, Derek Lim1, Anne Reiman1, Lawrence Seabra1, Kirsten Mckay1, Lynn Martin1, Ian Tomlinson2, Farida Latif1, Eamonn Maher1

1University of Birmingham, UK, 2University of Oxford, UK


Prophylaxis of neutropenic complications during CHOP-R chemotherapy using GCSF: a 3 year case-control study

Year:

Session type:

Kathryn Lang, Anne-Marie O'Hea, Helen Eagleton

Stoke Mandeville Hospital, Aylesbury, UK


Identification of potential colorectal cancer biomarkers using 2D gel electrophoresis analysis

Year:

Session type:

Lynda Ralton, Graeme Murray

University of Aberdeen, UK